Type 1 Diabetes (T1D)

Metabolic·MeSH: Diabetes Mellitus, Type 1

Prevalence

200.0 / 100K

Incidence

22.0 / 100K/yr

12 drugs in development·8 companies·9 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
ilet bionic pancreas	Beta Bionics Inc. (BBNX)
tzield	PROVENTION BIO, INC. (PBI)

Phase 3(2)

Drug	Company
cadisegliatin	vTv Therapeutics Inc. (VTVT)
cadisegliatin 800 mg qd	vTv Therapeutics Inc. (VTVT)

Phase 1(1)

Drug	Company
nnc0497-0040	Novo Nordisk A/S (NVO)

Preclinical(5)

Drug	Company
bihormonal ilet	Beta Bionics Inc. (BBNX)
ilt1	Lineage Cell Therapeutics, Inc. (LCTX)
patch pump	Beta Bionics Inc. (BBNX)
sig-002	Sigilon Therapeutics, Inc. (SGTX)
vicapsyn	Vicapsys Life Sciences, Inc. (VICP)

BLA Filed(1)

Drug	Company
teplizumab	PROVENTION BIO, INC. (PBI)

Phase 1/Phase 2(1)

Drug	Company
CTX211	CRISPR Therapeutics AG (CRSP)

BioSniper tracks 12 drugs in development for Type 1 Diabetes (T1D) across 8 companies.

There are 9 clinical trials targeting Type 1 Diabetes (T1D) tracked by BioSniper.

The estimated prevalence of Type 1 Diabetes (T1D) is approximately 200.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.